newsfilter
← Latest News
GlobeNewswire·

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026Successfully completed